아플리버셉트 주사 후 발생한 비감염성 안내염
Noninfectious Endophthalmitis after Intravitreal Injection of Aflibercept
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
목적: 유리체내 아플리버셉트(aflibercept) 주사 후 발생한 비감염성 안내염을 보고하고자 한다. 증례요약: 67세 남자 환자가 우안의 습성 나이관련 황반변성으로 유리체내 aflibercept 주사 2일 후 시작된 경미한 통증이 동반된 시력저하를 주소로 내원하였다. 세극등 현미경 검사에서 결막충혈은 경미하였고 전방 및 유리체내 중등도의 염증세포소견이 관찰되었으나 통증 및 전방축농은 없었다. 비감염성 안내염으로 진단하였고 점안 항생제 및 점안스테로이드를 사용하였다. 치료 3일 후 전방내 염증세포는 빠르게 감소하는 양상이었고, 치료 10일 후 전방 및 유리체내 염증 소견은 관찰되지 않았으며, 교정시력이 0.1로 이전의 시력만큼 회복되었다. 결론: 유리체내 aflibercept 주사 후 발생한 비감염성 안내염은 점안 스테로이드 치료를 통해 비교적 빠른 호전을 기대할 수 있다.
Abstract
Purpose: To report a case of noninfectious endophthalmitis after intravitreal injection of aflibercept. Case summary: A 67-year-old male patient presented with sudden vision loss 2 days after intravitreal aflibercept injection for neovascular age-related macular degeneration. Mild conjunctival injection and moderate inflammation in the anterior chamber were noted, but he had no ocular pain or hypopyon. The patient was diagnosed with noninfectious endophthalmitis and successfully treated with topical antibiotics and topical steroid eye drops. The infection was apparently cleared at 3 days. At 10 days after the initial presentation, his vision loss resolved completely. Conclusions: Noninfectious endophthalmitis after intravitreal injection of aflibercept can be treated with topical steroids.
참고문헌 (15)
- Heier JS., "Intravitreal aflibercept(VEGF trap-eye)in wet age-related macular degeneration", Ophthalmology, 119, pp.2537~2548 (2012)
- Goldberg RA., "Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes", Am J Ophthalmol, 158, pp.733.e1~737.e1 (2014)
- Hahn P., "Postmarketing analysis of aflibercept-related sterile intraocular inflammation", JAMA Ophthalmol, 133, pp.421~426 (2015)
- Hahn P., "Aflibercept-related sterile inflammation", Ophthalmology, 120, pp.1100.e1-5~1101.e1-5 (2013)
- Fine HF., "Frequency and characteristics of intraocular inflammation after aflibercept injection", Retina, 35, pp.681~686 (2015)
- Bakri SJ., "Intraocular inflammation following intravitreal injection of bevacizumab", Graefes Arch Clin Exp Ophthalmol, 246, pp.779~781 (2008)
- Kay CN., "Uveitis following intravitreal bevacizumab : a non-infectious cluster", Ophthalmic Surg Lasers Imaging, 42, pp.292~296 (2011)
- Fauser S., "Intraocular inflammation after intravitreal ranibizumab injections", Acta Ophthalmol, 89, pp.e98~e99 (2011)
- Sharma S., "Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections", Can J Ophthalmol, 47, pp.275~279 (2012)
- Sutter FK., "Pseudo-endophthalmitis after intravitreal injection of triamcinolone", Br J Ophthalmol, 87, pp.972~974 (2003)
- Roth DB., "Noninfectious endophthalmitis associated with intravitreal triamcinolone injection", Arch Ophthalmol, 121, pp.1279~1282 (2003)
- Nelson ML., "Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection", Retina, 23, pp.686~691 (2003)
- Damasceno N., "Anterior uveitis after treatment ofage-related macular degeneration with ranibizumab and bevacizumab : uncommon complication", Clin Ophthalmol, 6, pp.1201~1205 (2012)
- Cunningham MA., "Sequential, acute noninfectious uveitis associated with separate intravitreal injections of bevacizumab and ranibizumab", Retin Cases Brief Rep, 7, pp.355~358 (2013)
- Celia F, "Eylea’s roaring rollout : though questions remain on long-term dosing, aflibercept has taken the retinal world by storm", Retinal Physician, 9, pp.38~41 (2012)